News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
602,713 Results
Type
Article (40889)
Company Profile (91)
Press Release (561727)
Multimedia
Podcasts (165)
Webinars (26)
Section
Business (175311)
Career Advice (2209)
Deals (28922)
Drug Delivery (121)
Drug Development (62389)
Employer Resources (150)
FDA (14239)
Job Trends (12728)
News (287205)
Policy (27333)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2241)
Academic (1)
Accelerated approval (41)
ADA (35)
Adcomms (25)
Allergies (157)
Alliances (45173)
ALS (183)
Alzheimer's disease (1553)
Antibody-drug conjugate (ADC) (385)
Approvals (14640)
Artificial intelligence (683)
ASCO (259)
Autoimmune disease (281)
Automation (56)
Bankruptcy (268)
Best Places to Work (9938)
BIOSECURE Act (15)
Biosimilars (190)
Biotechnology (65)
Bladder cancer (173)
Brain cancer (61)
Breast cancer (685)
Cancer (5251)
Cardiovascular disease (418)
Career advice (1898)
Career pathing (42)
CAR-T (289)
CDC (74)
Celiac Disease (2)
Cell therapy (817)
Cervical cancer (43)
Clinical research (54103)
Collaboration (1980)
Company closure (8)
Compensation (724)
Complete response letters (56)
COVID-19 (2824)
CRISPR (98)
C-suite (1012)
Cystic fibrosis (118)
Data (7066)
Decentralized trials (3)
Denatured (51)
Depression (146)
Dermatology (81)
Diabetes (549)
Diagnostics (7191)
Digital health (55)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (304)
Drug pricing (181)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (78787)
Editorial (71)
Employer branding (20)
Employer resources (137)
Events (92083)
Executive appointments (964)
FDA (17512)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (13)
Frontotemporal dementia (32)
Funding (1502)
Gene editing (202)
Generative AI (67)
Gene therapy (643)
GLP-1 (926)
Government (4312)
Grass and pollen (6)
Guidances (393)
Healthcare (15746)
Hematology (159)
HIV (75)
Huntington's disease (47)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (89)
Immunology and inflammation (243)
Immuno-oncology (92)
Indications (178)
Infectious disease (3185)
Inflammatory bowel disease (178)
Inflation Reduction Act (15)
Influenza (141)
Intellectual property (238)
Interviews (404)
IPO (13167)
IRA (45)
Job creations (3094)
Job search strategy (1557)
JPM (61)
Kidney cancer (17)
Labor market (86)
Layoffs (491)
Leadership (42)
Legal (6763)
Liver cancer (82)
Longevity (26)
Lung cancer (681)
Lymphoma (383)
Machine learning (51)
Management (52)
Manufacturing (954)
MASH (187)
Medical device (11100)
Medtech (11226)
Mergers & acquisitions (16853)
Metabolic disorders (1357)
mRNA (243)
Multiple sclerosis (169)
NASH (15)
Neurodegenerative disease (384)
Neuropsychiatric disorders (89)
Neuroscience (2870)
NextGen: Class of 2026 (5278)
Non-profit (3851)
Now hiring (52)
Obesity (603)
Opinion (324)
Ovarian cancer (202)
Pain (200)
Pancreatic cancer (280)
Parkinson's disease (312)
Partnered (30)
Patents (485)
Patient recruitment (529)
Peanut (53)
People (49965)
Pharmaceutical (23)
Pharmacy benefit managers (26)
Phase 1 (16650)
Phase 2 (23332)
Phase 3 (18762)
Pipeline (8395)
Policy (322)
Postmarket research (2186)
Preclinical (7073)
Press Release (70)
Prostate cancer (320)
Psychedelics (48)
Radiopharmaceuticals (331)
Rare diseases (968)
Real estate (4917)
Recruiting (61)
Regulatory (21030)
Reports (43)
Research institute (2086)
Resumes & cover letters (341)
Rett syndrome (41)
RNA editing (22)
RSV (94)
Schizophrenia (154)
Series A (251)
Series B (181)
Service/supplier (5)
Sickle cell disease (102)
Special edition (25)
Spinal muscular atrophy (139)
Sponsored (48)
Startups (2938)
State (1)
Stomach cancer (14)
Supply chain (108)
Tariffs (80)
The Weekly (111)
Vaccines (1298)
Venture capital (108)
Weight loss (396)
Women's health (111)
Worklife (20)
Date
Last 7 days (491)
Last 30 days (2120)
Last 365 days (25456)
2026 (12543)
2025 (25377)
2024 (28634)
2023 (32564)
2022 (42847)
2021 (46328)
2020 (45272)
2019 (38436)
2018 (28962)
2017 (27346)
2016 (26754)
2015 (31392)
2014 (25870)
2013 (22256)
2012 (22969)
2011 (23242)
2010 (21835)
Location
Africa (858)
Alabama (86)
Alaska (6)
Arizona (268)
Arkansas (11)
Asia (34440)
Australia (6002)
California (10911)
Canada (3180)
China (1104)
Colorado (515)
Connecticut (534)
Delaware (320)
Europe (82374)
Florida (1697)
Georgia (374)
Hawaii (1)
Idaho (45)
Illinois (896)
India (93)
Indiana (534)
Iowa (20)
Japan (508)
Kansas (113)
Kentucky (46)
Louisiana (40)
Maine (86)
Maryland (1361)
Massachusetts (7910)
Michigan (370)
Minnesota (549)
Mississippi (5)
Missouri (121)
Montana (31)
Nebraska (21)
Nevada (131)
New Hampshire (69)
New Jersey (3159)
New Mexico (30)
New York (2939)
North Carolina (1443)
North Dakota (10)
Northern California (5455)
Ohio (356)
Oklahoma (22)
Oregon (32)
Pennsylvania (2168)
Puerto Rico (15)
Rhode Island (39)
South America (1071)
South Carolina (59)
Southern California (4378)
Tennessee (187)
Texas (1816)
United States (39515)
Utah (371)
Vermont (1)
Virginia (288)
Washington D.C. (70)
Washington State (884)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
602,713 Results for "chiron corporation now novartis vaccines and diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
May 7, 2026
·
8 min read
Deals
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
It’s the latest Big Pharma deal for molecular glue technology and Novartis’ second with Orionis Biosciences, after first linking up in March 2020. The backloaded agreement will see Novartis pay $40 million upfront.
June 11, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
June 12, 2026
·
2 min read
·
Tristan Manalac
COVID-19
FDA assembles vaccine experts to update COVID-19 formulation
The FDA will convene its vaccines advisory panel to discuss seasonal COVID-19 vaccines—a surprise move after Health Secretary and vaccine skeptic Robert F. Kennedy, Jr. overhauled a separate vaccine committee.
May 27, 2026
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
May 26, 2026
·
9 min read
·
Heather McKenzie
Earnings
Novartis’ sales dip as generics pressure intensifies, radioequivalents loom
Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.
April 28, 2026
·
2 min read
·
Tristan Manalac
Huntington’s disease
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval
Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more than 50%. Analysts say the decision to initiate a last-stage trial reflects a lack of confidence in an accelerated FDA nod.
April 29, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Novartis Keeps Deals Coming With $2B Excellergy Takeover
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in children and adults.
March 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
February 20, 2026
·
3 min read
Manufacturing
Niowave, fresh from Novartis deal, starts building $75M radioisotope plant
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
May 26, 2026
·
2 min read
·
Nick Paul Taylor
1 of 60,272
Next
